AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15533901 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy intervention
Number of subjects: 220
Study 15533901 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 220
Study 11533326 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ferrous sulfate drops (40 mg elemental iron once daily)
Number of subjects: 557
Study 11533326 — intervention group
Group type: COMPARATOR
Intervention: 3-times-daily ferrous sulfate drops (40 mg elemental iron total per day)
Number of subjects: 557
Study 11533326 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ferrous sulfate drops
Number of subjects: 557
Study 11533326 — intervention group
Group type: COMPARATOR
Intervention: 3-times-daily ferrous sulfate drops
Number of subjects: 557
Study 9190002 — intervention group
Group type: EXPERIMENTAL
Intervention: Amor criteria
Number of subjects: 157
Study 9190002 — intervention group
Group type: EXPERIMENTAL
Intervention: ESSG criteria
Number of subjects: 157
Study 9190002 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Amor and ESSG criteria
Number of subjects: 157
Study 2223330 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 50 micrograms kg‐1 followed by an infusion of 50 micrograms kg‐1 h‐1 and propofol infusion
Number of subjects: 51
Study 2223330 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.6 mg added to premedication
Number of subjects: 51
Study 6989245 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose intravenous sodium cephalothin
Number of subjects: 79
Study 6989245 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose intravenous sodium cephalothin
Number of subjects: 79
Study 6989245 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oral metronidazole
Number of subjects: 79
Study 6989245 — intervention group
Group type: COMPARATOR
Intervention: Control groups from previous studies
Number of subjects: 79
Study 31407871 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tadalafil orally once daily for 12 weeks
Number of subjects: 53
Study 28583031 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib dose intensity ≥4.6 mg/m2/cycle
Number of subjects: 0
Study 28583031 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib dose intensity <4.6 mg/m2/cycle
Number of subjects: 0
Study 29280434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation
Number of subjects: 6
Study 29280434 — intervention group
Group type: COMPARATOR
Intervention: Active Surveillance
Number of subjects: 6
Study 25456560 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ascending doses of 3.7 to 55.7 mg of samidorphan
Number of subjects: 46
Study 25456560 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple ascending doses of 10 or 20 mg of samidorphan for 7 days
Number of subjects: 46
Study 25456560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 46
Study 24268098 — intervention group
Group type: EXPERIMENTAL
Intervention: HARP
Number of subjects: 40
Study 24268098 — intervention group
Group type: COMPARATOR
Intervention: LDN
Number of subjects: 40
Study 21902546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal brachytherapy (ILBT) using ¹²⁵I seed strands
Number of subjects: 34
Study 21902546 — intervention group
Group type: COMPARATOR
Intervention: Control group with only biliary stent insertion
Number of subjects: 34
Study 19755964 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with 23-valent pneumococcal polysaccharide vaccines (PSVs) in Group A (immunosuppressed patients)
Number of subjects: 64
Study 19755964 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with 23-valent pneumococcal polysaccharide vaccines (PSVs) in Group B (non-immunosuppressed patients)
Number of subjects: 64
Study 19755964 — intervention group
Group type: COMPARATOR
Intervention: Immunization with 23-valent pneumococcal polysaccharide vaccines (PSVs) in Group C (healthy controls)
Number of subjects: 64
Study 19755964 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with 23-valent pneumococcal polysaccharide vaccines (PSVs) in Group A
Number of subjects: 64
Study 18616088 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of 20 mg cinnarizine and 40 mg dimenhydrinate (one tablet three times daily) for 4 weeks
Number of subjects: 37
Study 18616088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 18616088 — intervention group
Group type: COMPARATOR
Intervention: Betahistine (12 mg betahistine dimesylate, one tablet three times daily) for 4 weeks
Number of subjects: 37
Study 18616088 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of 20 mg cinnarizine and 40 mg dimenhydrinate
Number of subjects: 37
Study 16139582 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation plus treatment as usual (VNS+TAU)
Number of subjects: 329
Study 16139582 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 329
Study 11846847 — intervention group
Group type: EXPERIMENTAL
Intervention: Emdogain
Number of subjects: 36
Study 11846847 — intervention group
Group type: COMPARATOR
Intervention: Placebo (propylene glycol alginate)
Number of subjects: 36
Study 9885792 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms/kg
Number of subjects: 0
Study 9885792 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine 29 micrograms/kg
Number of subjects: 0
Study 9885792 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms/kg
Number of subjects: 0
Study 9885792 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 and 5 micrograms/kg
Number of subjects: 0
Study 9885792 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 0
Study 9885792 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 and Guanfacine 29 micrograms/kg
Number of subjects: 0
Study 8771612 — intervention group
Group type: EXPERIMENTAL
Intervention: Early sleep deprivation (sleep 03:00-07:00 h)
Number of subjects: 41
Study 8771612 — intervention group
Group type: EXPERIMENTAL
Intervention: Late sleep deprivation (sleep 21:00-01:00 h)
Number of subjects: 41
Study 8771612 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers (control group)
Number of subjects: 41
Study 1466871 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 8)
Number of subjects: 14
Study 1466871 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 6)
Number of subjects: 14
Study 3971683 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral narcotic analgesics plus ibuprofen 400 mg four times daily
Number of subjects: 10
Study 3971683 — intervention group
Group type: COMPARATOR
Intervention: Oral narcotic analgesics alone (placebo)
Number of subjects: 10
Study 30709627 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-information video
Number of subjects: 200
Study 30709627 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 200
Study 29741912 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized capsules of Stachys lavandulifolia
Number of subjects: 29
Study 29741912 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 29
Study 26903580 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy (LG) with D2 lymphadenectomy
Number of subjects: 1056
Study 26903580 — intervention group
Group type: COMPARATOR
Intervention: Open gastrectomy (OG) with D2 lymphadenectomy
Number of subjects: 1056
Study 25212696 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-PST intervention to reduce harmful/hazardous alcohol use
Number of subjects: 0
Study 25212696 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal-attention wellness intervention
Number of subjects: 0
Study 25212696 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 21450577 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise testing
Number of subjects: 55
Study 21450577 — intervention group
Group type: COMPARATOR
Intervention: Bicycle exercise testing
Number of subjects: 55
Study 20448177 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand washing (physical cleansing)
Number of subjects: 0
Study 17647055 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of chili powder along with antibiotics and analgesics
Number of subjects: 60
Study 17647055 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics and analgesics alone
Number of subjects: 60
Study 15999594 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy alone or in combination with hormone therapy
Number of subjects: 0
Study 15999594 — intervention group
Group type: COMPARATOR
Intervention: Standard hormone therapy
Number of subjects: 0
Study 15999594 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy and chemotherapy
Number of subjects: 0
Study 11920978 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT with exercise and maintenance
Number of subjects: 114
Study 11920978 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT with exercise
Number of subjects: 114
Study 11920978 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT with maintenance
Number of subjects: 114
Study 11920978 — intervention group
Group type: COMPARATOR
Intervention: CBT only
Number of subjects: 114
Study 9859533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin 3 x 1 g (14 subjects)
Number of subjects: 155
Study 9859533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan 2 x 1 g (43 subjects)
Number of subjects: 155
Study 9859533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefalotin 3 x 2 g for 24 hours (27 subjects)
Number of subjects: 155
Study 9859533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefalotin 3 x 2 g for 72 hours (41 subjects)
Number of subjects: 155
Study 9859533 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 subjects) without prophylaxis
Number of subjects: 155
Study 7881264 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA) mouthwash, 5 ml solution at 10% in olive oil, used for five minutes, three times a day for eight weeks.
Number of subjects: 0
Study 7881264 — intervention group
Group type: COMPARATOR
Intervention: Acetonide of triamcinolone 01% in aqueous solution (control group).
Number of subjects: 0
Study 1983349 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pentagastrin (0.6 microgram.kg/h) with placebo
Number of subjects: 12
Study 1983349 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pentagastrin (0.6 microgram.kg/h) with ranitidine 300 mg
Number of subjects: 12
Study 1983349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1983349 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 12
Study 530855 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step treatment
Number of subjects: 204
Study 530855 — intervention group
Group type: COMPARATOR
Intervention: Planned interval treatment
Number of subjects: 204
Study 30506696 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management program
Number of subjects: 425
Study 30506696 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 425
Study 27677220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerec infinident
Number of subjects: 10
Study 27677220 — intervention group
Group type: COMPARATOR
Intervention: Conventional
Number of subjects: 10
Study 27677220 — intervention group
Group type: EXPERIMENTAL
Intervention: Lava
Number of subjects: 10
Study 27677220 — intervention group
Group type: EXPERIMENTAL
Intervention: iTero
Number of subjects: 10
Study 27677220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerec inLab
Number of subjects: 10
Study 25847678 — intervention group
Group type: EXPERIMENTAL
Intervention: Thio-Ben plus cryotherapy (TC)
Number of subjects: 64
Study 25847678 — intervention group
Group type: COMPARATOR
Intervention: Glucantime plus cryotherapy (GC)
Number of subjects: 64
Study 24368466 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal, 250 mg twice daily for 2 years
Number of subjects: 130
Study 24368466 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 2 years
Number of subjects: 130
Study 21807773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous slow 5 IU oxytocin bolus over 1 minute and additional 40 IU oxytocin infusion in 500 mL of 0.9% saline solution over 4 hours (bolus and infusion)
Number of subjects: 2069
Study 21807773 — intervention group
Group type: COMPARATOR
Intervention: 5 IU oxytocin bolus over 1 minute and 500 mL of 0.9% saline solution over 4 hours (placebo infusion) (bolus only)
Number of subjects: 2069
Study 19102515 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 or 40 mg/day
Number of subjects: 507
Study 19102515 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 or 40 mg/day with or without hydrochlorothiazide
Number of subjects: 507
Study 19102515 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 507
Study 16883966 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation (0.625 mg/day)
Number of subjects: 101
Study 16883966 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamin compound supplementation (riboflavin 0.625 mg/day, thiamin 0.512 mg/day, nicotinic acid 0.365 mg/day, folic acid 0.13 mg/day)
Number of subjects: 101
Study 16883966 — intervention group
Group type: COMPARATOR
Intervention: Supplemental control group
Number of subjects: 101
Study 15219499 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive group
Number of subjects: 456
Study 15219499 — intervention group
Group type: COMPARATOR
Intervention: Nonhypertensive group
Number of subjects: 456
Study 11725851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociceptive Trigeminal Inhibition Tension Suppression System
Number of subjects: 0
Study 9469527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sustained-release morphine
Number of subjects: 6
Study 8184813 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 5 mg (target 20 mg)/day (n = 20)
Number of subjects: 41
Study 8184813 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 21)
Number of subjects: 41
Study 3309233 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation (30 to 40 mg/kg/24 hr)
Number of subjects: 21
Study 31964660 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy with standard podiatry care over 24 weeks
Number of subjects: 78
Study 31964660 — intervention group
Group type: COMPARATOR
Intervention: None (Substudy 1)
Number of subjects: 78
Study 31964660 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 78
Study 29535130 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus 9 weeks of trastuzumab
Number of subjects: 232
Study 29535130 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 232
Study 29535130 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of both treatment arms
Number of subjects: 232
Study 27871584 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation (SV)
Number of subjects: 39
Study 27871584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV)
Number of subjects: 39
Study 27871584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 39
Study 27871584 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 39
Study 24157957 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleglitazar plus single-dose warfarin
Number of subjects: 12
Study 24157957 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 12
Study 23021692 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrospinous fixation (SSF)
Number of subjects: 168
Study 23021692 — intervention group
Group type: COMPARATOR
Intervention: Total mesh (Prolift; Gynecare/Ethicon)
Number of subjects: 168
Study 20418072 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day for 3 weeks
Number of subjects: 15
Study 20418072 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 15
Study 20418072 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 15
Study 18714059 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg) plus vitamin B(12) (0.4 mg)
Number of subjects: 3096
Study 18714059 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B(6) (40 mg)
Number of subjects: 3096
Study 18714059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3096
Study 15817716 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial bout of plyometric exercise in men
Number of subjects: 20
Study 15817716 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial bout of plyometric exercise in boys
Number of subjects: 20
Study 15817716 — intervention group
Group type: EXPERIMENTAL
Intervention: Second bout of plyometric exercise
Number of subjects: 20
Study 12421060 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseball batting simulation
Number of subjects: 0
Study 12421060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitch speed variance
Number of subjects: 0
Study 12421060 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotation cues
Number of subjects: 0
Study 12421060 — intervention group
Group type: EXPERIMENTAL
Intervention: History of previous pitches and pitch count
Number of subjects: 0
Study 12421060 — intervention group
Group type: EXPERIMENTAL
Intervention: Expertise
Number of subjects: 0
Study 10339732 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - Beclomethasone dipropionate (BDP) 0.4 mg/day
Number of subjects: 48
Study 10339732 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ICS)
Number of subjects: 48
Study 8984131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 193
Study 8984131 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 193
Study 2117204 — intervention group
Group type: EXPERIMENTAL
Intervention: Curosurf (200 mg/kg)
Number of subjects: 0
Study 2117204 — intervention group
Group type: COMPARATOR
Intervention: High ventilator pressure and oxygen requirements
Number of subjects: 0
Study 323793 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza A vaccine administered intranasally
Number of subjects: 46
Study 323793 — intervention group
Group type: COMPARATOR
Intervention: Killed subunit vaccine
Number of subjects: 46
Study 323793 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 46
Study 323793 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza A vaccine
Number of subjects: 46
Study 323793 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza A vaccine and Killed subunit vaccine
Number of subjects: 46
Study 31625653 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted antibiotic stewardship intervention
Number of subjects: 0
Study 31625653 — intervention group
Group type: COMPARATOR
Intervention: Public commitment
Number of subjects: 0
Study 31625653 — intervention group
Group type: EXPERIMENTAL
Intervention: Postimplementation survey
Number of subjects: 0
Study 31625653 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplementation phase
Number of subjects: 0
Study 31625653 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation outcome metrics
Number of subjects: 0
Study 30879569 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine n-3 PUFAs (2.6 g daily)
Number of subjects: 132
Study 30879569 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 132
Study 28588101 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 egg per day for 6 months
Number of subjects: 163
Study 28588101 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 163
Study 24840781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate 6 g/day
Number of subjects: 166
Study 24840781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate 4 g/day
Number of subjects: 166
Study 24840781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 24800383 — intervention group
Group type: EXPERIMENTAL
Intervention: Email-linked website intervention with ten consecutive weekly emails and two motivational phone calls
Number of subjects: 339
Study 24800383 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 339
Study 21780170 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal voluntary contractions (10 contractions sustained for 20 seconds) with transcranial magnetic stimulation (TMS) delivered at 5 second intervals.
Number of subjects: 10
Study 21780170 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) for assessing central fatigue.
Number of subjects: 10
Study 19757432 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed response adaptive design with a variance-penalized criterion
Number of subjects: 0
Study 19757432 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed design
Number of subjects: 0
Study 17019594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/day for 2 weeks)
Number of subjects: 18
Study 15023583 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 17
Study 11300391 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (20 microg x kg(‐1) body weight)
Number of subjects: 1334
Study 11300391 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 1334
Study 10211008 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 21, 12 and 6 mg kg‐1 h‐1 for a minimum of 2 hours
Number of subjects: 20
Study 10211008 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 20
Study 10150182 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg b.i.d., oral)
Number of subjects: 60
Study 10150182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3127417 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified FSH (225 IU daily for 10 days)
Number of subjects: 10
Study 3127417 — intervention group
Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotropin (hMG; 225 IU daily for 10 days)
Number of subjects: 10